Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
Hong WEN
Hong WEN



Livzon Pharmaceutical Group Inc.

Dr. Hong Wen has been a scientific lead and senior reviewer since joined FDA in 2013.  His review disciplines cover DMFs, ANDAs, NDAs, supplements, citizen petitions and controlled correspondences.  His research responsibilities focus on the impact of drug delivery on therapeutic performance of generic drug products, such as bioequivalence (BE) guidance development, ANDA reviews, and post-marketing investigations.  Prior to joining FDA in 2013, Hong has worked 11 years in pharmaceutical industry and has contributed to multiple IND/IMPD/NDA filings including nine NDA approvals. During his tenure in Novartis, he was project leader of multiple pharmaceutical development teams and a core member of Novartis TRD Science & Technology committee.  In 2002, he received his Ph.D. in Industrial and Physical Pharmacy from Purdue University. In April 2018, he joined Livzon Pharmaceuticals as Chief Scientific Officer.